| pubmed-article:15763644 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15763644 | lifeskim:mentions | umls-concept:C0028833 | lld:lifeskim |
| pubmed-article:15763644 | lifeskim:mentions | umls-concept:C0039286 | lld:lifeskim |
| pubmed-article:15763644 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15763644 | lifeskim:mentions | umls-concept:C1419115 | lld:lifeskim |
| pubmed-article:15763644 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:15763644 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:15763644 | pubmed:dateCreated | 2005-3-14 | lld:pubmed |
| pubmed-article:15763644 | pubmed:abstractText | The insulin-like growth factor (IGF)-system was evaluated in 150 breast cancer patients participating in a randomised phase III trial comparing octreotide pamoate and tamoxifen with tamoxifen+placebo. Alterations in the IGF-system in the two treatment arms and individual changes with respect to outcome were compared. Serum IGF-I and -II, free IGF-I, and insulin-like growth factor binding protein 1-3 (IGFBP1-3) were measured by radioimmmunoassay (RIA)/immunoradiometric assay (IRMA) and IGFBPs by Western ligand blots (WLB) before and during treatment. Combined treatment caused a higher increase in IGFBP-1 and larger suppression of total and free IGF-I, IGF-II, and IGFBP-3 (P<0.01 for all), but less suppression of IGFBP-2 (P<0.05) compared with tamoxifen monotherapy. An increase in IGFBP-2 25% was associated with decreased progression-free survival (PFS) in the total patient population and combined treatment group. Similar response rates and time to progression in the treatment arms suggests moderate suppression of circulating IGF-I has no influence on clinical outcome. | lld:pubmed |
| pubmed-article:15763644 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15763644 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15763644 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15763644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15763644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15763644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15763644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15763644 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15763644 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15763644 | pubmed:issn | 0959-8049 | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:SommerHH | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:BajettaEE | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:MietlowskiWW | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:BondHH | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:SzakolczaiII | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:GuastallaJ... | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:BaltaliEE | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:OttestadLL | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:LønningP EPE | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:CsepreghyMM | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:PinterTT | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:HelleS ISI | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:BryceCC | lld:pubmed |
| pubmed-article:15763644 | pubmed:author | pubmed-author:KlijnJ G MJG | lld:pubmed |
| pubmed-article:15763644 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15763644 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:15763644 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15763644 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15763644 | pubmed:pagination | 694-701 | lld:pubmed |
| pubmed-article:15763644 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:meshHeading | pubmed-meshheading:15763644... | lld:pubmed |
| pubmed-article:15763644 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15763644 | pubmed:articleTitle | Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy. | lld:pubmed |
| pubmed-article:15763644 | pubmed:affiliation | Department of Medicine, Section of Oncology, Haukeland University Hospital, N-5021 Bergen, Norway. | lld:pubmed |
| pubmed-article:15763644 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15763644 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15763644 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:15763644 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15763644 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:15763644 | pubmed:publicationType | Clinical Trial, Phase III | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15763644 | lld:pubmed |
